The University of Pittsburgh pilot trial (n=7, open-label, non-randomized) published in Nature Medicine demonstrates that cervical epidural spinal cord stimulation can yield immediate 32% gains in arm strength and reduced spasticity in chronic stroke survivors, even 5+ years post-event, with under nine hours of training. This small-sample safety study (no serious adverse events) highlights assistive rather than curative effects via enhanced residual corticospinal signaling, yet mainstream coverage fixates on acute-phase interventions while overlooking chronic-phase data. Related work in spinal cord injury populations (e.g., Harkema et al., Lancet 2011, n=4, and subsequent RCTs) shows overlapping mechanisms of sensory afferent amplification, suggesting stroke applications tap similar spared pathways missed by standard rehab. A 2023 Pitt interim report and broader observational cohorts (e.g., in Stroke journal) reinforce modest functional carryover, though conflicts of interest around device manufacturers warrant scrutiny. The trial's non-RCT design limits causal claims, but patterns indicate stimulation as a bridge technology for the 400,000 annual U.S. chronic cases where conventional therapy plateaus.